Molecules 2012-01-01

Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents.

Dahong Li, Lei Wang, Hao Cai, Yihua Zhang, Jinyi Xu

Index: Molecules 17(6) , 7556-68, (2012)

Full Text: HTML

Abstract

To search for novel nitric oxide (NO) releasing anti-tumor agents, a series of novel furoxan/oridonin hybrids were designed and synthesized. Firstly, the nitrate/nitrite levels in the cell lysates were tested by a Griess assay and the results showed that these furoxan-based NO-releasing derivatives could produce high levels of NO in vitro. Then the anti-proliferative activity of these hybrids against four human cancer cell lines was also determined, among which, 9 h exhibited the most potential anti-tumor activity with IC₅₀ values of 1.82 µM against K562, 1.81 µM against MGC-803 and 0.86 µM against Bel-7402, respectively. Preliminary structure-activity relationship was concluded based on the experimental data obtained. These results suggested that NO-donor/natural product hybrids may provide a promising approach for the discovery of novel anti-tumor agents.


Related Compounds

Related Articles:

[Anti-tumor effect of tanshinone II A, tetrandrine, honokiol, curcumin, oridonin and paeonol on leukemia cell lines].

2012-05-01

[Sichuan Da Xue Xue Bao. Yi Xue Ban 43(3) , 362-6, (2012)]

Induction of human CYP3A4 by huperzine A, ligustrazine and oridonin through pregnane X receptor-mediated pathways.

2014-07-01

[Pharmazie 69(7) , 532-6, (2014)]

The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells.

2013-02-01

[J. Gastroenterol. 48(2) , 182-92, (2013)]

Nitric oxide augments oridonin-induced efferocytosis by human histocytic lymphoma U937 cells via autophagy and the NF-κB-COX-2-IL-1β pathway.

2012-10-01

[Free Radic. Res. 46(10) , 1207-19, (2012)]

Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.

2012-09-01

[Int. J. Oncol. 41(3) , 949-58, (2012)]

More Articles...